- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.10.25 | Earnings roundup: Alnylam's down day, Neurocrine's head scratch and Biogen's 'low quality' win | ||
| 30.10.25 | Lilly hikes revenue forecasts on booming obesity drug sales | ||
| 30.10.25 | FDA places formal hold on two Intellia CRISPR trials | ||
| 30.10.25 | Novo tops Pfizer with $6.5B bid for Metsera | ||
| 29.10.25 | FDA, aiming to lower drug costs, moves to speed approval of biosimilars | ||
| 29.10.25 | Lilly aligns with Walmart in bid to broaden access to discounted Zepbound | ||
| 29.10.25 | BridgeBio chalks up another win for its rare disease research | ||
| 28.10.25 | GSK adds to COPD drug push with Empirico deal | ||
| 28.10.25 | Merck kidney cancer drug succeeds in two large trials | ||
| 28.10.25 | Incyte trims pipeline; Zenas surges on MS drug results | ||
| 28.10.25 | Zag Bio emerges with plans to treat immune disease by targeting the thymus | ||
| 27.10.25 | BioMarin, following sluggish sales, to offload hemophilia gene therapy | ||
| 27.10.25 | Intellia pauses two CRISPR drug studies after safety scare | ||
| 27.10.25 | Bayer receives FDA approval for non-hormonal menopause therapy | ||
| 27.10.25 | BridgeBio to seek approval of limb-girdle drug following new study data | ||
| 27.10.25 | Hemab collects another $157M to go after 'underserved' blood diseases | ||
| 27.10.25 | Community pharmacies and BioPharma: Advancing whole-patient care together | ||
| 27.10.25 | Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease | ||
| 24.10.25 | Biogen licenses a possible immune drug from OrbiMed-backed biotech | ||
| 24.10.25 | Adverum, hammered by gene therapy downturn, sells to Lilly in unusual deal | ||
| 24.10.25 | Sanofi says 'soft' start to fall immunizations slowed vaccine sales | ||
| 24.10.25 | Chugai buys a kidney biotech; ICER targets rising launch prices | ||
| 24.10.25 | FDA clears return of GSK's once-withdrawn multiple myeloma drug | ||
| 23.10.25 | Ventyx shares soar after study suggests cardiovascular benefits for experimental drug | ||
| 22.10.25 | Sanofi drug acquired in buyout succeeds in rare disease trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .